Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Patients with G719X alterations experienced longer TTD and OS with afatinib than osimertinib. In contrast, patients with L861Q alterations had longer TTD with osimertinib. In AM + CM pts, TTD and OS with osimertinib were longer than afatinib, suggesting that classical mutations may be driving the outcomes. Atypical EGFR mutations may warrant distinct treatment recommendations based on the specific mutation(s) identified, but more studies are needed.
Authors
- Lova Sun (ORCID: https://orcid.org/0000-0002-5015-2964)
- Wei‐Ting Hwang (ORCID: https://orcid.org/0000-0003-2829-2167)
- Connor B. Grady (ORCID: https://orcid.org/0000-0001-8407-846X)
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Fangdi Sun (ORCID: https://orcid.org/0000-0002-5917-6209)
- Melina E. Marmarelis (ORCID: https://orcid.org/0000-0003-2187-3583)
- Jared Weiss (ORCID: https://orcid.org/0000-0003-2961-4447)
- Adam Barsouk (ORCID: https://orcid.org/0000-0003-2333-7530)
- Charų C. Aggarwal (ORCID: https://orcid.org/0000-0003-2579-7581)
- Tejas Patil (ORCID: https://orcid.org/0000-0003-4389-1010)
- Alan G. Watts
- Stephen V. Liu (ORCID: https://orcid.org/0000-0002-4852-3914)
- Dara L. Aisner (ORCID: https://orcid.org/0000-0001-5203-5932)
- Kristen Ashley Marrone (ORCID: https://orcid.org/0000-0001-5319-824X)
- Vamsidhar Velcheti (ORCID: https://orcid.org/0000-0002-6589-0759)
- William Tompkins (ORCID: https://orcid.org/0009-0007-8381-6054)
- Jorge J. Nieva (ORCID: https://orcid.org/0000-0003-1605-4719)
- Omar Elghawy (ORCID: https://orcid.org/0000-0002-0786-8035)
- Liza Cosca Villaruz (ORCID: https://orcid.org/0000-0001-7456-523X)
- D. Ross Camidge (ORCID: https://orcid.org/0000-0003-3430-3213)
- Lauren Reed-Guy
- Corey J. Langer (ORCID: https://orcid.org/0000-0002-8483-6811)
- Krishna Chandrasekhara
- Geoffrey Liu (ORCID: https://orcid.org/0000-0002-2603-7296)
- Aditi Singh (ORCID: https://orcid.org/0000-0001-7438-2863)
- Devalben Patel
- Roger B. Cohen
- Amanda Hermann
- William Schwartzman
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Southern California (US)
- University Health Network (CA)
- Georgetown University (US)
- Hospital of the University of Pennsylvania (US)
- Georgetown University Medical Center (US)
- Princess Margaret Cancer Centre (CA)
- Southwestern Medical Center (US)
- Dana-Farber/Harvard Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Tennessee Oncology (US)
- Stanford Medicine (US)
- Johns Hopkins Hospital (US)
- Southwestern Medical Center (US)
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center
- University of Colorado Anschutz Medical Campus (US)
- New York University (US)
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University Medical Center (US)
- University of Colorado Denver (US)
- Stanford University (US)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108551
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- LUNGevity Foundation
- AstraZeneca
- Takeda Pharmaceutical Company